Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  sirolimus
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 76 for your search:
Start Over
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
Phase: Phase IV
Type: Prevention
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 0468H1-407, NCT00129961
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-Based Immunosuppressive Protocol
Phase: Phase IV
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: PROSKIN 01, NCT00866684
De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: #4279, NCT00328770
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Closed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: BMTCTN0801, U01HL069294, U01HL069294-06, NCT01106833
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: 2003.333, NCT00133887
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: SiLVER05, EudraCT Number:, 2005-005362-36, NCT00355862
Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 1 to under 22 at first relapse
Sponsor: NCI, Other
Protocol IDs: ASCT0431, NCI-2009-01068, CDR0000500131, COG-PBMTC-ONCO51, COG-ASCT0431, U10CA098543, NCT00382109
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 2 to 55
Sponsor: NCI, Other
Protocol IDs: BMTCTN0402, U01HL069294, U01HL069294-05, NCT00406393
Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: RDCRN 5702, RLD 5702, 1 U54 RR019498-01, NCT00414648
Sirolimus in Treating Patients With Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000257255, P30CA016042, UCLA-0203078, NCI-G02-2114, NCT00047073
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Other
Protocol IDs: 04-16, NCT00409994
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000557423, P30CA016042, UCLA-0604104, OSI3781s, NCT00509431
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 080078, 08-C-0078, NCT00923273
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Supportive care
Status: Completed
Age: Per primary treatment protocol
Sponsor: NCI, Other
Protocol IDs: 1811.00, FHCRC-1811.00, CDR0000378004, NCT00089037
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: 100180, 10-D-0180, NCT01195922
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 1012-24; IUCRO-0307, NCT01303965
Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: GEIS-24, 2009-017232-41, NCT01684449
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas
Phase: Phase II
Type: Treatment
Status: Closed
Age: 4 to 35
Sponsor: NCI
Protocol IDs: 020259, 02-C-0259, NCI-02-C-0259, NCT00047372, NCT00043979
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 1938.00, NCI-2010-00268, P30CA015704, P01CA018029, FHCRC-1938.00, 5887, NCT00105001
Sirolimus in Treating Patients With Angiomyolipoma of the Kidney
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: NCI, Other
Protocol IDs: CDR0000440080, DFCI-04298, WYETH-C-0468H1-101899, NCT00126672
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Phase: Phase II
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: 05-154, NCT00133367
Rapamycin in Combination With Low-Dose Aracytin in Elderly Acute Myeloid Leukemia Patients
Phase: Phase II
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: Other
Protocol IDs: 0402008, GOELAMS, PHRC, NCT00235560
Individualized Drug Treatment Selection Process for Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: JHOC-J0507, CDR0000455000, P30CA006973, JHOC-J0507, JHOC-05041402, J0507, NCT00276744
Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-1135.cc, NCT00353301
Start Over